CD19 and neoplasm: Interestingly, the tumor was still positive for CD19 and CD20 antigens by flow cytometry despite treatment with prior CD19 CAR-T and CD20 bispecific T-cell engager (BTCE) targeted therapies, possibly suggesting that resistance to therapy was achieved by tumor microenvironment rather than antigen loss.